US Stock MarketDetailed Quotes
CLDI Calidi Biotherapeutics
- 1.350
- +0.170+14.42%
Close Nov 1 16:00 ET
- 1.380
- +0.030+2.22%
Post 20:02 ET
12.57MMarket Cap-164P/E (TTM)
1.510High1.150Low2.90MVolume1.240Open1.180Pre Close3.85MTurnover39.46%Turnover RatioLossP/E (Static)9.31MShares26.30052wk High-1.07P/B9.94MFloat Cap0.73052wk Low--Dividend TTM7.36MShs Float137.900Historical High--Div YieldTTM30.51%Amplitude0.730Historical Low1.325Avg Price1Lot Size
Calidi Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -6.21%-5.49M | -23.30%-3.83M | -104.20%-26.98M | -33.80%-5.19M | -13.52M | -5.17M | -3.11M | -69.98%-13.21M | -3.88M | -61.09%-7.77M |
| Net income from continuing operations | 53.87%-5.77M | -11.81%-7.23M | -14.90%-29.22M | -6.10%-8.23M | ---2.02M | ---12.5M | ---6.46M | -132.57%-25.43M | ---7.76M | -37.75%-10.93M |
| Operating gains losses | ---- | ---- | --476K | --5K | ---- | ---- | ---- | ---- | ---- | -1,112.96%-655K |
| Depreciation and amortization | 3.85%378K | 104.37%374K | 396.44%1.26M | 343.90%364K | --345K | --364K | --183K | 65.36%253K | --82K | 30.77%153K |
| Other non cash items | -99.46%16K | -92.56%16K | -13.97%1.93M | -165.81%-1.46M | --201K | --2.98M | --215K | 209.22%2.25M | --2.21M | 844.16%727K |
| Change In working capital | 17.16%-777K | 19,070.00%1.92M | -274.89%-6.24M | 1,066.99%2.99M | ---8.3M | ---938K | --10K | 225.34%3.57M | ---309K | 16.08%1.1M |
| -Change in prepaid assets | 102.48%7K | 656.54%1.58M | -1,405.29%-2.22M | -137.84%-352K | ---1.3M | ---282K | ---283K | 141.46%170K | ---148K | -736.73%-410K |
| -Change in payables and accrued expense | -20.86%-533K | 125.68%580K | -244.01%-4.9M | 1,381.37%2.06M | ---6.77M | ---441K | --257K | 125.55%3.4M | ---161K | 51.61%1.51M |
| -Change in other current liabilities | -16.74%-251K | -761.11%-238K | --872K | --1.28M | ---226K | ---215K | --36K | --0 | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -6.21%-5.49M | -23.30%-3.83M | -104.20%-26.98M | -33.80%-5.19M | ---13.52M | ---5.17M | ---3.11M | -69.98%-13.21M | ---3.88M | -61.09%-7.77M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 96.35%-5K | 3.24%-478K | 78.26%-35K | -63K | -243K | -137K | -129.77%-494K | -161K | 44.59%-215K |
| Net PPE purchase and sale | --0 | 96.35%-5K | -36.68%-585K | 56.52%-70K | ---72K | ---306K | ---137K | -107.77%-428K | ---161K | 41.31%-206K |
| Net business purchase and sale | ---- | ---- | --9K | --0 | ---- | ---- | ---- | --0 | --0 | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
| Net other investing changes | ---- | ---- | 248.48%98K | ---- | ---- | ---- | ---- | -633.33%-66K | ---- | 75.68%-9K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | 96.35%-5K | 3.24%-478K | 78.26%-35K | ---63K | ---243K | ---137K | -129.77%-494K | ---161K | 44.59%-215K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -20.91%5.2M | -20.52%3.01M | 140.29%29.04M | -168.49%-2.96M | 21.64M | 6.58M | 3.79M | 23.21%12.09M | 4.32M | 108.86%9.81M |
| Net issuance payments of debt | -306.34%-1.82M | 36.29%3.18M | -34.90%899K | -255.59%-2.3M | ---17K | --883K | --2.33M | -21.09%1.38M | --1.48M | -6.87%1.75M |
| Net common stock issuance | ---- | ---- | --2.76M | --0 | --2.76M | ---- | ---- | --0 | --0 | -98.83%35K |
| Net preferred stock issuance | ---- | ---- | --24.5M | --0 | --19.35M | ---- | ---- | --0 | --0 | --0 |
| Cash dividends paid | --0 | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | 4,384.00%2.24M | --0 | 146.49%281K | --0 | --50K | --50K | --181K | 14.00%114K | --0 | --100K |
| Net other financing activities | -89.67%153K | -112.67%-162K | -94.30%604K | -123.22%-660K | ---1.5M | --1.48M | --1.28M | 33.65%10.59M | --2.84M | 198,225.00%7.93M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -20.91%5.2M | -20.52%3.01M | 140.29%29.04M | -168.49%-2.96M | --21.64M | --6.58M | --3.79M | 23.21%12.09M | --4.32M | 108.86%9.81M |
| Net cash flow | ||||||||||
| Beginning cash position | 19.70%1.36M | 267.29%2.17M | -73.63%590K | 3,355.00%10.37M | --2.29M | --1.14M | --590K | 432.62%2.24M | --300K | -55.03%420K |
| Current changes in cash | -125.37%-294K | -250.46%-823K | 197.66%1.58M | -3,000.35%-8.18M | --8.06M | --1.16M | --547K | -189.02%-1.62M | --282K | 452.22%1.82M |
| Effect of exchange rate changes | -30.00%-13K | --17K | 76.92%-6K | -337.50%-19K | --23K | ---10K | --0 | -550.00%-26K | --8K | -233.33%-4K |
| End cash Position | -53.89%1.05M | 19.70%1.36M | 267.29%2.17M | 267.29%2.17M | --10.37M | --2.29M | --1.14M | -73.63%590K | --590K | 432.62%2.24M |
| Free cash flow | -0.27%-5.49M | -18.25%-3.84M | -102.08%-27.57M | -30.20%-5.26M | ---13.59M | ---5.48M | ---3.24M | -70.95%-13.64M | ---4.04M | -54.14%-7.98M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
